Rapamycin Failed a Huge Human Longevity Test. Here's the Catch
Rapamycin is the darling of the longevity world, but its biggest real-world human test just came back unimpressive. Among 4,885 kidney transplant patients on rapamycin and 6,589 who weren't, median survival age was 64.6 vs 64.3 years, a statistically similar result after adjustment. Over a median 11-year follow-up with 6,443 deaths, researchers saw no meaningful lifespan gain. But the study involved transplant patients on immunosuppressive regimens and was observational, so it can't settle whether low, intermittent dosing works in healthy people. Here's what it does and doesn't tell you.
Apple Peel Compound Ursolic Acid Shields Muscle in Obese Mice
An apple peel compound, ursolic acid, just showed a muscle-sparing effect in obese mice, and its cousin oleanolic acid did too. In high-fat-diet mice and fat-stressed muscle cells, both improved glucose handling, reduced muscle atrophy and supported mitochondria. The proposed mechanisms include reviving IRS/AKT/mTOR signaling, restraining FOXO1-driven breakdown and a possible link to PSMB1. But this is animal and cell work only, and it does not show these compounds protect human muscle or treat sarcopenia.
Rapamycin 'Can't Reach the Brain'? Why That Myth Is Falling Apart
"Rapamycin can't reach the brain" is one of the most repeated claims in longevity circles, and a new review says it rests on the wrong measurement. The drug is rarely detectable in cerebrospinal fluid, but the authors explain why that doesn't mean it stays out of brain tissue. Human glioblastoma samples, seizure control in tuberous sclerosis, PET scans in Alzheimer's, and blood flow in APOE4 carriers all point to real activity in the brain. The big catch is that nobody has directly measured the drug in healthy human brain tissue at therapeutic doses. Here's what the evidence supports, what it doesn't, and who should think twice.